Andere talen Allogene Therapeutics, Inc.

Aandelen

ALLO

US0197701065

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,46 ^USD	-1,42%		-13,28%	+7,79%

15/03	Allogene Therapeutics dient een aanvraag in voor $500 miljoen gemengde Shelf	MT
14/03	Transcript : Allogene Therapeutics, Inc., Q4 2023 Earnings Call, Mar 14, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Allogene Therapeutics Announces Q2 Investor Conference Participation	09/04
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index	18/03
Allogene Therapeutics Files $500 Million Mixed Shelf	15/03
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops	14/03
Allogene Therapeutics: Q4 Earnings Snapshot	14/03
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update	14/03
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	14/03
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease	12/03
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update	05/03
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	28/02
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	28/02
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia	19/02
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments	16/02
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia	16/02
Allogene Therapeutics, Inc. Announces Restate Financial Statements for the Years Ended December 31, 2020, 2021 and 2022 and Interim Quarters During 2022 and 2023	16/02
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences	16/01
North American Morning Briefing : Boeing Drags -2-	08/01
Aktien New York: Anleger nach US-Wirtschaftsdaten hin- und hergerissen	05/01
Aktien New York: Trübe Stimmung im Servicesektor wirkt positiv	05/01
Allogene Therapeutics to Lay off 22% of Workforce; Partners With Foresight to Develop in Vitro Diagnostic	05/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Allogene Therapeutics, Inc.

Aandelen

ALLO

US0197701065

Andere talen

Filters